Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02684994 · ClinicalTrials.gov registry record · NA

Client-directed Cognitive Processing Therapy

A NA study, sponsored by University of Indianapolis.

Completed
Registry status
NA
Development phase
55
Enrollment target

NCT02684994: Completed NA study, sponsored by University of Indianapolis.

NCT02684994 is a NA study that has completed, run by University of Indianapolis. The registered enrollment target is 55 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02684994, a NA study, has completed, sponsored by University of Indianapolis.

COMPLETED
Registry status
NA
Development phase
55 participants
Enrollment target

Study Summary

This study will take place over approximately 6 months and includes 3 assessment appointments (where information will be gathered, but no direct treatment provided) and 12 treatment sessions of cognitive processing therapy if eligible.

Primary Outcome

Clinician administered clinical interview (Clinician Administered PTSD Scale) assessing PTSD symptoms

Interventions

  • BEHAVIORAL Cognitive Processing Therapy

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2014-10
Est. Completion 2018-08-01
Phase NA
University of Indianapolis

9 total trials

What the finished NCT02684994 record still lists

NCT02684994 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 1 intervention - of which Cognitive Processing Therapy is the first listed.

NCT02684994 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02684994 about?

NCT02684994 is a clinical study titled "Client-directed Cognitive Processing Therapy". This study will take place over approximately 6 months and includes 3 assessment appointments (where information will be gathered, but no direct treatment provided) and 12 treatment sessions of cognitive processing therapy if eligible.

What is the current status of trial NCT02684994?

This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2014-10. Estimated completion is 2018-08-01.

What interventions are being tested in trial NCT02684994?

The interventions under investigation include: Cognitive Processing Therapy (BEHAVIORAL).

Who is sponsoring clinical trial NCT02684994?

This trial is sponsored by University of Indianapolis, which has 9 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02684994's enrollment target sits among peer trials

55 1264th of 2000 higher than 733 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01638676 · 55 participants · Phase 1

    A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

  • NCT01906385 · 55 participants · Phase 1

    Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

  • NCT03007030 · 55 participants · Phase 2

    Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

  • NCT03152058 · 55 participants · Phase 2

    IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02684994, the US trial registry maintained by the National Library of Medicine. NCT02684994 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.